Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.
Community viral load
Hepatitis C control
Hepatitis C surveillance
Hepatitis C virus
Novel epidemiologic measures
Systematic review
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
02
11
2019
revised:
23
01
2020
accepted:
27
01
2020
pubmed:
3
2
2020
medline:
25
5
2021
entrez:
3
2
2020
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) infection is the most prevalent blood-borne infection and causes more deaths than any other infectious disease in the US. Incident HCV infection in the US increased nearly 300 % between 2010 and 2015, Community viral load (CVL) measures have been developed for HIV to measure both transmission risk and treatment engagement in programs or areas. This paper presents a systematic review exploring the published literature on CVL constructs applied to HCV epidemiology and proposes novel CVL measures for HCV. A systematic review was conducted of electronic databases; the search sought to identify published literature on HCV which discussed or applied CVL measures to HCV epidemiology. Novel CVL measures were constructed to apply to HCV. No reports examining quantitative measures of HCV CVL were identified. Using the HIV CVL literature and the specific characteristics of HCV epidemiology, five HCV CVL measures are proposed. Narrower measures focusing on those engaged-in-care may be useful for program evaluation and broader measures including undiagnosed people may be useful for surveillance of HCV transmission potential. Despite their potential value, CVL constructs have not yet formally been developed and applied to HCV epidemiology. The CVL measures proposed here could serve as valuable HCV program and surveillance measures. There is a need for informative surveillance measures to enhance policy and public health responses to achieve HCV control. Further study of these proposed HCV CVL measures to HCV epidemiology is warranted.
Sections du résumé
BACKGROUND
Hepatitis C virus (HCV) infection is the most prevalent blood-borne infection and causes more deaths than any other infectious disease in the US. Incident HCV infection in the US increased nearly 300 % between 2010 and 2015, Community viral load (CVL) measures have been developed for HIV to measure both transmission risk and treatment engagement in programs or areas.
OBJECTIVE
This paper presents a systematic review exploring the published literature on CVL constructs applied to HCV epidemiology and proposes novel CVL measures for HCV.
STUDY DESIGN AND SETTING
A systematic review was conducted of electronic databases; the search sought to identify published literature on HCV which discussed or applied CVL measures to HCV epidemiology. Novel CVL measures were constructed to apply to HCV.
RESULTS
No reports examining quantitative measures of HCV CVL were identified. Using the HIV CVL literature and the specific characteristics of HCV epidemiology, five HCV CVL measures are proposed. Narrower measures focusing on those engaged-in-care may be useful for program evaluation and broader measures including undiagnosed people may be useful for surveillance of HCV transmission potential.
CONCLUSION
Despite their potential value, CVL constructs have not yet formally been developed and applied to HCV epidemiology. The CVL measures proposed here could serve as valuable HCV program and surveillance measures. There is a need for informative surveillance measures to enhance policy and public health responses to achieve HCV control. Further study of these proposed HCV CVL measures to HCV epidemiology is warranted.
Identifiants
pubmed: 32007842
pii: S1386-6532(20)30027-5
doi: 10.1016/j.jcv.2020.104285
pmc: PMC7195813
mid: NIHMS1554624
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104285Subventions
Organisme : NIDA NIH HHS
ID : P30 DA011041
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007233
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None to declare.
Références
Am J Public Health. 2014 Nov;104(11):2226-32
pubmed: 25211717
Lancet. 2011 Jan 8;377(9760):108-9
pubmed: 20630580
J Virol. 2006 Mar;80(6):2654-64
pubmed: 16501075
MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):465-469
pubmed: 28493854
Dig Dis Sci. 2001 Aug;46(8):1677-83
pubmed: 11508667
AIDS. 2014 Apr 24;28(7):1049-57
pubmed: 24566097
J Virus Erad. 2018 Jul 1;4(3):193-195
pubmed: 30050685
Int J Epidemiol. 2012 Apr;41(2):504-13
pubmed: 22253314
Can J Gastroenterol Hepatol. 2015 Apr;29(3):125-9
pubmed: 25855874
Am J Public Health. 2014 Jun;104(6):e75-82
pubmed: 24825236
PLoS One. 2010 Jun 10;5(6):e11068
pubmed: 20548786
AIDS. 2012 Jan 28;26(3):345-53
pubmed: 22008660
BMJ. 2009 Apr 30;338:b1649
pubmed: 19406887
AIDS. 2015 Nov;29(17):2335-45
pubmed: 26258525
Epidemiol Infect. 2006 Apr;134(2):249-57
pubmed: 16490127
PLoS One. 2012;7(12):e53284
pubmed: 23285274
Air Qual Atmos Health. 2012 Jun;5(2):203-216
pubmed: 22662023
Syst Rev. 2012 Feb 09;1:2
pubmed: 22587842
Clin Infect Dis. 2014 Nov 15;59(10):1411-9
pubmed: 25114031
Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45
pubmed: 23884064
Lancet. 2010 Aug 14;376(9740):532-9
pubmed: 20638713
Hepat Mon. 2016 Aug 13;16(8):e40959
pubmed: 27799966
J Viral Hepat. 2011 Jan;18(1):32-41
pubmed: 20196806
BMJ. 1997 Aug 9;315(7104):333-7
pubmed: 9270453
Hepatology. 2010 Nov;52(5):1564-72
pubmed: 21038409
HIV Med. 2015 Jul;16(6):346-54
pubmed: 25688937
Lancet. 1997 Mar 22;349(9055):825-32
pubmed: 9121257
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
N Engl J Med. 2011 Jun 23;364(25):2405-16
pubmed: 21696307
Drug Alcohol Depend. 2009 Mar 1;100(3):204-13
pubmed: 19004579
Clin Infect Dis. 2012 Nov 15;55(10):1408-16
pubmed: 22893583
Clin Infect Dis. 2016 May 15;62(10):1287-1288
pubmed: 26936668
AIDS. 2015 Mar 27;29(6):723-31
pubmed: 25849835
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):400-2
pubmed: 22732466
Hepatology. 2005 Dec;42(6):1446-52
pubmed: 16317675
Lancet Infect Dis. 2013 May;13(5):459-64
pubmed: 23537801
Addiction. 2007 May;102(5):778-85
pubmed: 17506155
Eur J Clin Microbiol Infect Dis. 1996 Nov;15(11):884-7
pubmed: 8997565
Drug Alcohol Depend. 2011 Dec 15;119(3):166-71
pubmed: 21724339
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
PLoS One. 2014 Jul 28;9(7):e103345
pubmed: 25068274
N Engl J Med. 2011 Mar 31;364(13):1195-206
pubmed: 21449783
Pediatr Infect Dis J. 2001 Jan;20(1):10-4
pubmed: 11176560
Clin Infect Dis. 2005 Nov 15;41(10):1423-30
pubmed: 16231252
Hepatology. 2013 Nov;58(5):1598-609
pubmed: 23553643
JAMA. 2000 Jul 26;284(4):450-6
pubmed: 10904508
J Hepatol. 2001 May;34(5):730-9
pubmed: 11434620
Hepatology. 2019 Mar;69(3):1020-1031
pubmed: 30398671
PLoS One. 2012;7(1):e29679
pubmed: 22291892
J Infect Dis. 2011 Dec 15;204(12):1819-21
pubmed: 22013223
Milbank Q. 2012 Dec;90(4):634-81
pubmed: 23216426
Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7
pubmed: 20425880
Open Forum Infect Dis. 2015 Jun 26;2(2):ofv089
pubmed: 26180831
Spat Spatiotemporal Epidemiol. 2013 Dec;7:11-24
pubmed: 24238078
Am J Public Health. 2018 Feb;108(2):175-181
pubmed: 29267061
Drug Alcohol Depend. 2016 Mar 1;160:127-34
pubmed: 26785634
Liver. 1999 Apr;19(2):104-9
pubmed: 10220739
AIDS. 2014 Jun 19;28(10):1509-19
pubmed: 24809629
Lancet. 2014 Nov 15;384(9956):1756-65
pubmed: 25078309
Lancet HIV. 2016 Apr;3(4):e152-4
pubmed: 27036988
J Gastroenterol Hepatol. 2002 May;17(5):617-9
pubmed: 12084037
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8
pubmed: 25950251
AIDS. 2013 Aug 24;27(13):2129-39
pubmed: 24384591
J Infect Dis. 2012 Feb 1;205(3):358-65
pubmed: 22241800
Semin Liver Dis. 2011 Nov;31(4):340-6
pubmed: 22189974
R I Med J (2013). 2014 Jan 05;98(1):26-30
pubmed: 25562057
N Engl J Med. 2011 Mar 31;364(13):1207-17
pubmed: 21449784
J Addict Dis. 2015;34(2-3):198-205
pubmed: 26075647
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e84-6
pubmed: 23666144
Lancet HIV. 2016 Apr;3(4):e183-90
pubmed: 27036994
Subst Use Misuse. 2015;50(7):899-902
pubmed: 26158751
Scand J Gastroenterol. 2002 Oct;37(10):1228-34
pubmed: 12408530
Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:173-7
pubmed: 26409061
Infect Control Hosp Epidemiol. 2010 Mar;31(3):203-32
pubmed: 20088696
Subst Use Misuse. 2015;50(7):825-38
pubmed: 25723309